130 related articles for article (PubMed ID: 23151832)
1. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
Tapaninen T; Karonen T; Backman JT; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2013 Jan; 23(1):19-24. PubMed ID: 23151832
[TBL] [Abstract][Full Text] [Related]
2. Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans.
Kim KA; Lee HM; Joo HJ; Park IB; Park JY
J Clin Pharmacol; 2013 Nov; 53(11):1186-93. PubMed ID: 23970434
[TBL] [Abstract][Full Text] [Related]
3. Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast.
Mougey EB; Lang JE; Wen X; Lima JJ
J Clin Pharmacol; 2011 May; 51(5):751-60. PubMed ID: 20974993
[TBL] [Abstract][Full Text] [Related]
4. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response.
Mougey EB; Feng H; Castro M; Irvin CG; Lima JJ
Pharmacogenet Genomics; 2009 Feb; 19(2):129-38. PubMed ID: 19151602
[TBL] [Abstract][Full Text] [Related]
5. Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children.
Li Q; Wang K; Shi HY; Wu YE; Zhou Y; Kan M; Zheng Y; Hao GX; Yang XM; Yang YL; Su LQ; Wang XL; Jacqz-Aigrain E; Zhou J; Zhao W
Drug Des Devel Ther; 2019; 13():4405-4411. PubMed ID: 31920289
[TBL] [Abstract][Full Text] [Related]
6. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
[TBL] [Abstract][Full Text] [Related]
7. Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
Rebello S; Leon S; Hariry S; Dahlke M; Jarugula V
J Clin Pharmacol; 2011 Feb; 51(2):218-28. PubMed ID: 20413453
[TBL] [Abstract][Full Text] [Related]
8. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Clin Pharmacol Ther; 2010 Sep; 88(3):339-42. PubMed ID: 20664534
[TBL] [Abstract][Full Text] [Related]
9. Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
Jarugula V; Yeh CM; Howard D; Bush C; Keefe DL; Dole WP
J Clin Pharmacol; 2010 Dec; 50(12):1358-66. PubMed ID: 20150520
[TBL] [Abstract][Full Text] [Related]
10. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.
Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S
Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248
[TBL] [Abstract][Full Text] [Related]
11. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
Karonen T; Filppula A; Laitila J; Niemi M; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724
[TBL] [Abstract][Full Text] [Related]
12. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
[TBL] [Abstract][Full Text] [Related]
13. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren.
Tapaninen T; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2010 Sep; 66(9):865-70. PubMed ID: 20496145
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
Vaidyanathan S; Warren V; Yeh C; Bizot MN; Dieterich HA; Dole WP
J Clin Pharmacol; 2007 Feb; 47(2):192-200. PubMed ID: 17244770
[TBL] [Abstract][Full Text] [Related]
15. Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects.
Ayalasomayajula S; Yeh CM; Vaidyanathan S; Flannery B; Dieterich HA; Howard D; Bedigian MP; Dole WP
J Clin Pharmacol; 2008 Jul; 48(7):799-811. PubMed ID: 18490495
[TBL] [Abstract][Full Text] [Related]
16. Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
Laitinen A; Niemi M
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):9-13. PubMed ID: 20560925
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
[TBL] [Abstract][Full Text] [Related]
18. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.
Rebello S; Zhao S; Hariry S; Dahlke M; Alexander N; Vapurcuyan A; Hanna I; Jarugula V
Eur J Clin Pharmacol; 2012 May; 68(5):697-708. PubMed ID: 22124880
[TBL] [Abstract][Full Text] [Related]
19. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects.
Limoges D; Dieterich HA; Yeh CM; Vaidyanathan S; Howard D; Dole WP
Int J Clin Pharmacol Ther; 2008 May; 46(5):252-8. PubMed ID: 18538111
[TBL] [Abstract][Full Text] [Related]
20. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
Kim KA; Park PW; Kim KR; Park JY
Br J Clin Pharmacol; 2007 Mar; 63(3):339-45. PubMed ID: 16981900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
